8-K filing — Rafael Holdings, Inc. (RFL)
Filed: 2026-11-09 AccNo: 0001213900-26-117552 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Rafael Holdings Announced Topline Efficacy And Safety Data From Its Cyclo Therapeutics Subsidiary’s Phase 3 TransportNPC Study Evaluating Trappsol Cyclo In 94 Patients Diagnosed With Niemann-Pick Disease Type C; Trappsol Cyclo Did Not Achieve Statistical Significance
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Rafael Holdings, Inc. announced it will participate in a fireside chat and host one-on-one meetings with institutional investors at the Guggenheim 3rd Annual Healthcare Innovation Conference.
Rafael Holdings Reports Fiscal 2026 Financial Results
Rafael Holdings, Inc. announced its financial results for the fourth quarter and full fiscal year ended July 31, 2026, reporting a narrowed net loss compared to the prior year.
Rafael Holdings Subsidiary Submits NDA for Trappsol® Cyclo™
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the FDA for remibetadex to treat Niemann-Pick Disease Type C.
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
Why Is Rafael Stock Falling Wednesday?
Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.